Analysis - RBC 15 NOV 2016 — http://docdro.id/4wfaB3P
Extract —
'Investment summary
- ProMetic is targeting high-value/margin orphan markets instead of competing on volume like major players in the market. While ProMetic initially intends to go head to head for a few products (such as IVIG and alpha 1-antitrypsin) with higher revenues (~$300–400) per liter, its greatest yield advantage is in rare proteins that command a higher price (~$1,500+) per liter of plasma. The incumbents are largely limited in their ability to extract these proteins. As such, the average revenues they can generate from one liter of plasma is ~$400 vs. ProMetic, which believes it can exceed $2,000 as more orphan drug proteins are commercialized.
- Disruptive technology has significant yield and cost advantages over established process/peers. PLI’s purification process is a well-established technology that has been used by clients to isolate proteins for well over two decades. Because pharmaceutical companies were focused on the development of other technologies, ProMetic is now able to bridge the gap and either license its technology to pharmaceutical companies or use its superior technology to isolate therapeutic proteins that pharmaceutical companies do not have the means to isolate. ProMetic’s technology provides higher yields than traditional technology and is able to separate proteins that are typically hard to isolate.
- Attractive from a risk profile perspective given that bioseparation technology is utilized in 12 approved products. ProMetic’s separation technology is utilized in 12 FDA/EMEA/etc approved products and several others are under development. This base business should continue to steadily improve as additional R&D efforts are initiated and product approvals occur.
- Significant number of potential catalysts in the next 12–36 months. ProMetic’s diverse business divisions have all seen significant clinical developments in the past 12 months, but we anticipate the bulk of catalytic events to occur over the next 12–36 months as both the plasma-derived therapeutics division and the small molecule therapeutics divisions of ProMetic could see substantial value-driving events such as positive clinical trial data, BLA/NDA filings, and FDA/EU approvals. All of these events would typically have an impact on stock price.
- Significant potential with PBI-4050; small molecule therapeutic. ProMetic’s lead small molecule candidate, PBI-4050, has seen extremely positive results in gold-standard animal models to date and has had strong results in Phase I trials. PBI-4050 is intended to treat fibrosis and other diseases involving an inflammatory response. Currently, PBI-4050 is being investigated in idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD) caused by Type 2 diabetes, and cystic fibrosis (CF) related diabetes (CFRD).'
_____________________________
**NOTE: [PBI-4050 anecdotal-only evidence here -- 1, 2 -- see posts by "walkingred"]
"I am absolutely serious.
He was being treated at Toronto General...and the doctors there were dumbfounded when he said he wanted to take 4050... they'd never heard of it, and were very very sceptical. The Dr's at TG (Scratins?) were in contact with Dr. Moran... I actually spoke with Dr. Moran myself over the phone, and then stayed present during subsequent phone calls (when I had the chance). They weren't as sure as Dr. Moran, but the patient was adament about it. Dr. Moran is a top class person and chartacter.
For a little nobody like me to fire off an email to Fred, only to be in touch with the big boys...to getting an uncle dosed... it was truly humbling, and I am proud to be part of the company.
Long story longer.... I believe there is now a trial base out of Toronto General because of my uncle... where originally he would have had to travel to Montreal, or Hamilton to get the goods.
He felt the effects of the first dose within an hour... couldn't pin point exactly at first, just a feeling of better.'
Jim |
